Shots:
- The global P-II (VALIANT) trial data assessed Verekitug vs PBO in 478 pts with severe asthma for ~60wks., with a minimum of 24wks. of treatment. Eligible pts could then enroll in the VALOUR LTE trial
- Trial met its 1EP, reducing annualized asthma exacerbation rates by 56% (100mg; Q12W) & 39% (400mg, Q24W), with FEV1 gains of 122mL & 139mL at Wk. 60 & FeNO reductions of mean 43.5% & 44.9% from baseline; 100mg Q24W improved AAER but not other endpoints
- At Wk. 24, pre-specified analyses showed statistically significant PBO-adjusted improvements in FEV1 & FeNO with 100mg Q12W & 400mg Q24W. Verekitug will advance in P-III for asthma & CRSwNP following planned regulatory interactions
Ref: Globenewswire |  Image: Upstream Bio  | Press Release
Related News: OrsoBio Reports P-IIa Trial Data on TLC-2716 in Severe Hypertriglyceridemia and Metabolic Liver Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
